Mechanism of Action
FGFR1c / Beta-Klotho Receptor Complex
fibroblast-growth-factor-21/" class="wiki-internal-link">FGF-21 signals through a receptor complex consisting of FGF receptor 1c (FGFR1c) and the co-receptor beta-Klotho. Unlike classical FGFs that signal in autocrine/paracrine fashion, FGF-21 functions as an endocrine hormone. Beta-Klotho expression determines tissue responsiveness, with adipose tissue, liver, and hypothalamus being primary targets. Receptor activation triggers PI3K/Akt and MAPK/ERK pathways.
Adipose Tissue Effects
In white adipose tissue, FGF-21 promotes lipolysis, reduces lipogenesis, and upregulates adiponectin secretion. In brown adipose tissue, FGF-21 enhances thermogenic UCP1 expression via PGC-1alpha activation, increasing energy expenditure. These combined effects produce the sustained fat loss observed in FGF-21 treatment models.
Hepatic and Systemic Metabolism
FGF-21 reduces hepatic lipogenesis by suppressing SREBP1c while activating fatty acid oxidation pathways. In the hypothalamus, FGF-21 modulates macronutrient preference, reducing simple carbohydrate intake. Circulating FGF-21 coordinates the fasting metabolic program across multiple tissues simultaneously.
Research Summary
NASH and Liver Disease
HumanPhase II trials of FGF-21 analogs (pegbelfermin, efruxifermin) showed significant reductions in liver fat by MRI-PDFF, fibrosis markers, and liver enzymes in NASH patients. Efruxifermin is in Phase III trials and showed 39% NASH resolution rates versus 7% placebo in Phase IIb.
Obesity and Metabolic Syndrome
HumanFGF-21 analogs produced meaningful weight loss (5-10% body weight in some trials), improved triglycerides, raised HDL cholesterol, and enhanced insulin sensitivity. Combination with GLP-1 agonists showed additive metabolic benefits in early studies.
Aging and Longevity
AnimalTransgenic mice with elevated FGF-21 live 30-40% longer than wild-type, with reduced age-related metabolic decline. Conversely, FGF-21 knockout mice show accelerated aging phenotypes. Whether exogenous FGF-21 extends healthspan in primates remains under investigation.
Calculate your FGF-21 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic research | 0.5-3 mg/kg | Daily x 4 weeks | Subcutaneous |
| Hepatic fat reduction | 1-6 mg/kg | Weekly (long-acting analog) | Subcutaneous |
Native FGF-21 has a short half-life; most clinical development uses PEGylated or fusion analogs for weekly or biweekly dosing.
Interactions
Safety Profile
FGF-21 analogs have been generally well tolerated in human trials. Reported side effects include injection site reactions, diarrhea, and dose-dependent increases in bone turnover markers. Nail and hair changes were noted at higher doses in early-phase trials. No serious adverse cardiovascular effects were seen. Long-term safety data are being generated in ongoing Phase III programs.
References
- [1]Kharitonenkov A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-1635.
- [2]Inagaki T, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415-425.
- [3]Harrison SA, et al. Efruxifermin in non-alcoholic steatohepatitis. N Engl J Med. 2023.